The Influenza Centre"> Influenza centre home
Stacks Image 263


The Influenza Centre in Bergen is an International Research Laboratory and Advisor for the Prevention, Control and Treatment of Influenza and Corona viruses. The Influenza Centre is a collaboration between the University of Bergen, The Haukeland University Hospital and the Department of Health.

The Centre is part of the Infection and Microbiology research gorup.

MÅL Norsk

Influensasenteret i Bergen er et internasjonalt forskningslaboratorium og rådgivende organ for beskyttelse, kontroll og behandling av influensa or Korona virus. Influensasenteret er et sammarbeid mellom Universitetet i Bergen, Haukeland Universitetssykehus og Helsedepartementet.

Stacks Image 56

COVID-19 research

The Influenza Centre is currently conducting research into the COVID-19 pandemic in Western Norway funded by Helse Vest, Trond Mohn Stiffetelse, Univeristy of Bergen and Haukeland University Hospital. Five institutions have joined competencies to build this interdisciplinary project that includes the University of Bergen (UiB), Haukeland University Hospital (HUS), Bergen Legevakt (BLV), Haraldsplass Deaconess Hospital (HDS), and Stavanger University Hospital (SUS).

Stacks Image 270

The first case of COVID-19 infection was identified in Bergen on 28th February prior to the declaration of pandemic on 11th March 2020. Rigorous testing of all suspected cases in the community was centralised in Bergen providing a unique opportunity to study the pandemic. Building on our experience from the swine influenza pandemic, our interdisciplinary consortium covering the community, hospitals and Universities aims to understand key clinical, epidemiological, and immunological characteristics of COVID-19 infection in the general population, hospitalised patients and frontline healthcare workers (HCW). We commenced our study on 6th March collecting baseline pre-exposure and demographics data and serum samples from 1000 HCW. These HCW have been followed up upon suspected or confirmed infection or we have collected exposure history and serum samples 6-8 weeks later. Serological assays have been established in which only infected people have antibodies and allowed us to map exposure. Exposure history and clinical symptoms and blood samples have been collected from all COVID-19 positive community cases up to Easter and their household and close contacts. We will define levels of population-based immunity to SARS-CoV-2 virus in HCW (exposed and/or infected), community and hospitalized patients and the durability of immunity. We will describe the prognostic factors for severe and life-threatening illness in hospitalized patients in Bergen and investigate immunological biomarkers for severe disease. Our immunological and epidemiological findings will provide vital information on the ability of the virus to spread in the Norwegian population and in health care services to inform future policy decisions.

Stacks Image 103



Stacks Image 97

The Influenza Center, University of Bergen and Haukeland University Hospital
The Laboratory Building, 5th Floor, N-5021 Bergen, Norway. Tel. +47 - 55974668